Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Preflucel Immunogenicity and Safety in Adults and Elderly
NCT00943657Phase 3Completed
- Sponsor
- Resilience Government Services
- Start
- Jun 2009
- Primary completion
- Jul 2009
- Modality
- Split/Subunit Vaccines, Recombinant Protein Vaccines
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of inactivated influenza vaccine (vero cell-derived) in influenza, sponsored by Resilience Government Services. Primary endpoints: Number of subjects demonstrating seroconversion at 21 days and Safety and tolerance of the vaccine at 21 days. Started Jun 2009; status: completed.
02
Drugs
inactivated influenza vaccine (vero cell-derived)
03
Conditions
influenza
Beyond the preview
Go deeper on NCT00943657.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00943657.